Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of JADE-001

Next Previous
Trial Profile

Study of JADE-001

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JADE-001 (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 07 Nov 2024 New trial record
  • 31 Oct 2024 According to a Aerovate Therapeutics media release, the company expects to initiate a clinical trial for JADE-001 in the second half of 2025 with initial data expected in the first half of 2026.
  • 31 Oct 2024 According to a Aerovate Therapeutics media release, the company and Jade Biosciences have entered into a definitive merger agreement for an all-stock transaction. The financing is expected to close immediately prior to completion of the merger, with the combined company's cash balance at closing anticipated to fund Jade's operations through 2027 and advance JADE-001 to initial clinical proof-of-concept.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top